nodes	percent_of_prediction	percent_of_DWPC	metapath
Furosemide—PGD—Methotrexate—urinary bladder cancer	0.192	0.332	CbGbCtD
Furosemide—SLC22A11—Methotrexate—urinary bladder cancer	0.057	0.0986	CbGbCtD
Furosemide—ABCC2—Carboplatin—urinary bladder cancer	0.0569	0.0984	CbGbCtD
Furosemide—ABCC2—Cisplatin—urinary bladder cancer	0.0486	0.0841	CbGbCtD
Furosemide—ABCC2—Etoposide—urinary bladder cancer	0.0478	0.0826	CbGbCtD
Furosemide—ALB—Fluorouracil—urinary bladder cancer	0.0357	0.0617	CbGbCtD
Furosemide—SLC22A8—Methotrexate—urinary bladder cancer	0.0332	0.0573	CbGbCtD
Furosemide—ABCC2—Doxorubicin—urinary bladder cancer	0.0326	0.0563	CbGbCtD
Furosemide—ABCC2—Methotrexate—urinary bladder cancer	0.0316	0.0546	CbGbCtD
Furosemide—SLC22A6—Methotrexate—urinary bladder cancer	0.0231	0.0399	CbGbCtD
Furosemide—ALB—Methotrexate—urinary bladder cancer	0.0197	0.034	CbGbCtD
Furosemide—SLC12A1—urine—urinary bladder cancer	0.0091	0.0767	CbGeAlD
Furosemide—SLC22A8—urine—urinary bladder cancer	0.00528	0.0445	CbGeAlD
Furosemide—CA14—prostate gland—urinary bladder cancer	0.00364	0.0307	CbGeAlD
Furosemide—CA5A—female reproductive system—urinary bladder cancer	0.00358	0.0302	CbGeAlD
Furosemide—SLC12A1—prostate gland—urinary bladder cancer	0.00327	0.0275	CbGeAlD
Furosemide—CA14—seminal vesicle—urinary bladder cancer	0.00308	0.0259	CbGeAlD
Furosemide—SLCO2A1—prostate gland—urinary bladder cancer	0.00301	0.0254	CbGeAlD
Furosemide—CA7—renal system—urinary bladder cancer	0.00298	0.0251	CbGeAlD
Furosemide—PGD—prostate gland—urinary bladder cancer	0.00269	0.0226	CbGeAlD
Furosemide—SLCO2A1—seminal vesicle—urinary bladder cancer	0.00255	0.0215	CbGeAlD
Furosemide—CA5B—prostate gland—urinary bladder cancer	0.00254	0.0214	CbGeAlD
Furosemide—SLC12A1—epithelium—urinary bladder cancer	0.0024	0.0202	CbGeAlD
Furosemide—SLC22A11—renal system—urinary bladder cancer	0.00229	0.0193	CbGeAlD
Furosemide—PGD—seminal vesicle—urinary bladder cancer	0.00227	0.0192	CbGeAlD
Furosemide—SLC12A1—renal system—urinary bladder cancer	0.00223	0.0188	CbGeAlD
Furosemide—SLCO2A1—epithelium—urinary bladder cancer	0.00221	0.0187	CbGeAlD
Furosemide—SLC12A1—urethra—urinary bladder cancer	0.00219	0.0184	CbGeAlD
Furosemide—CA9—female reproductive system—urinary bladder cancer	0.00209	0.0176	CbGeAlD
Furosemide—SLCO2A1—renal system—urinary bladder cancer	0.00205	0.0173	CbGeAlD
Furosemide—SLCO2A1—urethra—urinary bladder cancer	0.00202	0.017	CbGeAlD
Furosemide—CA12—renal system—urinary bladder cancer	0.00193	0.0163	CbGeAlD
Furosemide—PGD—smooth muscle tissue—urinary bladder cancer	0.0019	0.016	CbGeAlD
Furosemide—SLC22A8—prostate gland—urinary bladder cancer	0.0019	0.016	CbGeAlD
Furosemide—ABCC2—prostate gland—urinary bladder cancer	0.00185	0.0156	CbGeAlD
Furosemide—SLC22A11—female reproductive system—urinary bladder cancer	0.00183	0.0155	CbGeAlD
Furosemide—PGD—renal system—urinary bladder cancer	0.00183	0.0154	CbGeAlD
Furosemide—PGD—urethra—urinary bladder cancer	0.0018	0.0152	CbGeAlD
Furosemide—CA4—prostate gland—urinary bladder cancer	0.00176	0.0148	CbGeAlD
Furosemide—CA5B—urethra—urinary bladder cancer	0.0017	0.0144	CbGeAlD
Furosemide—SLCO2A1—female reproductive system—urinary bladder cancer	0.00165	0.0139	CbGeAlD
Furosemide—CA12—female reproductive system—urinary bladder cancer	0.00155	0.0131	CbGeAlD
Furosemide—CA1—renal system—urinary bladder cancer	0.00153	0.0129	CbGeAlD
Furosemide—SLCO2A1—vagina—urinary bladder cancer	0.00149	0.0125	CbGeAlD
Furosemide—CA4—seminal vesicle—urinary bladder cancer	0.00149	0.0125	CbGeAlD
Furosemide—PGD—female reproductive system—urinary bladder cancer	0.00147	0.0124	CbGeAlD
Furosemide—CA2—prostate gland—urinary bladder cancer	0.00146	0.0123	CbGeAlD
Furosemide—SLC22A5—prostate gland—urinary bladder cancer	0.00143	0.0121	CbGeAlD
Furosemide—CA5B—female reproductive system—urinary bladder cancer	0.00139	0.0117	CbGeAlD
Furosemide—PGD—vagina—urinary bladder cancer	0.00133	0.0112	CbGeAlD
Furosemide—SLC22A8—renal system—urinary bladder cancer	0.00129	0.0109	CbGeAlD
Furosemide—ABCC2—renal system—urinary bladder cancer	0.00126	0.0106	CbGeAlD
Furosemide—CA5B—vagina—urinary bladder cancer	0.00126	0.0106	CbGeAlD
Furosemide—CA2—seminal vesicle—urinary bladder cancer	0.00123	0.0104	CbGeAlD
Furosemide—CA1—female reproductive system—urinary bladder cancer	0.00123	0.0103	CbGeAlD
Furosemide—SLC22A5—seminal vesicle—urinary bladder cancer	0.00121	0.0102	CbGeAlD
Furosemide—CA4—renal system—urinary bladder cancer	0.0012	0.0101	CbGeAlD
Furosemide—CA4—urethra—urinary bladder cancer	0.00118	0.00991	CbGeAlD
Furosemide—CA2—epithelium—urinary bladder cancer	0.00107	0.00902	CbGeAlD
Furosemide—CA2—smooth muscle tissue—urinary bladder cancer	0.00103	0.00869	CbGeAlD
Furosemide—ABCC2—female reproductive system—urinary bladder cancer	0.00101	0.00851	CbGeAlD
Furosemide—CA2—renal system—urinary bladder cancer	0.000993	0.00837	CbGeAlD
Furosemide—SLC22A5—renal system—urinary bladder cancer	0.000977	0.00823	CbGeAlD
Furosemide—SLCO2A1—lymph node—urinary bladder cancer	0.000962	0.00811	CbGeAlD
Furosemide—SLC22A5—urethra—urinary bladder cancer	0.000959	0.00809	CbGeAlD
Furosemide—CA4—female reproductive system—urinary bladder cancer	0.000959	0.00808	CbGeAlD
Furosemide—PGD—lymph node—urinary bladder cancer	0.000858	0.00723	CbGeAlD
Furosemide—CA5B—lymph node—urinary bladder cancer	0.000813	0.00685	CbGeAlD
Furosemide—CA2—female reproductive system—urinary bladder cancer	0.000795	0.0067	CbGeAlD
Furosemide—SLC22A5—female reproductive system—urinary bladder cancer	0.000782	0.00659	CbGeAlD
Furosemide—CA2—vagina—urinary bladder cancer	0.000719	0.00606	CbGeAlD
Furosemide—CA1—lymph node—urinary bladder cancer	0.000718	0.00605	CbGeAlD
Furosemide—SLC22A5—vagina—urinary bladder cancer	0.000707	0.00596	CbGeAlD
Furosemide—ALB—lymph node—urinary bladder cancer	0.00063	0.00531	CbGeAlD
Furosemide—ABCC2—lymph node—urinary bladder cancer	0.000591	0.00498	CbGeAlD
Furosemide—CA4—lymph node—urinary bladder cancer	0.000561	0.00473	CbGeAlD
Furosemide—CA2—lymph node—urinary bladder cancer	0.000465	0.00392	CbGeAlD
Furosemide—SLC22A5—lymph node—urinary bladder cancer	0.000458	0.00386	CbGeAlD
Furosemide—Eosinophilia—Epirubicin—urinary bladder cancer	0.000228	0.000949	CcSEcCtD
Furosemide—Skin disorder—Etoposide—urinary bladder cancer	0.000227	0.000944	CcSEcCtD
Furosemide—Hyperhidrosis—Etoposide—urinary bladder cancer	0.000226	0.00094	CcSEcCtD
Furosemide—Pancreatitis—Epirubicin—urinary bladder cancer	0.000226	0.00094	CcSEcCtD
Furosemide—Feeling abnormal—Gemcitabine—urinary bladder cancer	0.000226	0.000938	CcSEcCtD
Furosemide—Orthostatic hypotension—Doxorubicin—urinary bladder cancer	0.000226	0.000937	CcSEcCtD
Furosemide—Photosensitivity reaction—Methotrexate—urinary bladder cancer	0.000225	0.000935	CcSEcCtD
Furosemide—Hypokalaemia—Doxorubicin—urinary bladder cancer	0.000225	0.000934	CcSEcCtD
Furosemide—Anorexia—Etoposide—urinary bladder cancer	0.000223	0.000927	CcSEcCtD
Furosemide—Diarrhoea—Thiotepa—urinary bladder cancer	0.000223	0.000926	CcSEcCtD
Furosemide—Toxic epidermal necrolysis—Doxorubicin—urinary bladder cancer	0.000222	0.000924	CcSEcCtD
Furosemide—Decreased appetite—Cisplatin—urinary bladder cancer	0.000222	0.000923	CcSEcCtD
Furosemide—Feeling abnormal—Fluorouracil—urinary bladder cancer	0.000222	0.000923	CcSEcCtD
Furosemide—Gastrointestinal disorder—Cisplatin—urinary bladder cancer	0.000221	0.000916	CcSEcCtD
Furosemide—Drowsiness—Methotrexate—urinary bladder cancer	0.00022	0.000913	CcSEcCtD
Furosemide—Hypotension—Etoposide—urinary bladder cancer	0.000219	0.000909	CcSEcCtD
Furosemide—Pain—Cisplatin—urinary bladder cancer	0.000218	0.000908	CcSEcCtD
Furosemide—Stevens-Johnson syndrome—Methotrexate—urinary bladder cancer	0.000218	0.000905	CcSEcCtD
Furosemide—Muscular weakness—Doxorubicin—urinary bladder cancer	0.000218	0.000905	CcSEcCtD
Furosemide—Body temperature increased—Gemcitabine—urinary bladder cancer	0.000217	0.0009	CcSEcCtD
Furosemide—Renal failure—Methotrexate—urinary bladder cancer	0.000216	0.000898	CcSEcCtD
Furosemide—Dizziness—Thiotepa—urinary bladder cancer	0.000215	0.000895	CcSEcCtD
Furosemide—Abdominal distension—Doxorubicin—urinary bladder cancer	0.000215	0.000893	CcSEcCtD
Furosemide—Urticaria—Fluorouracil—urinary bladder cancer	0.000214	0.000889	CcSEcCtD
Furosemide—Pollakiuria—Epirubicin—urinary bladder cancer	0.000213	0.000885	CcSEcCtD
Furosemide—Body temperature increased—Fluorouracil—urinary bladder cancer	0.000213	0.000885	CcSEcCtD
Furosemide—Eosinophilia—Doxorubicin—urinary bladder cancer	0.000211	0.000878	CcSEcCtD
Furosemide—Sweating—Methotrexate—urinary bladder cancer	0.000211	0.000875	CcSEcCtD
Furosemide—Photosensitivity reaction—Epirubicin—urinary bladder cancer	0.000211	0.000875	CcSEcCtD
Furosemide—Feeling abnormal—Cisplatin—urinary bladder cancer	0.00021	0.000875	CcSEcCtD
Furosemide—Paraesthesia—Etoposide—urinary bladder cancer	0.00021	0.000873	CcSEcCtD
Furosemide—Pancreatitis—Doxorubicin—urinary bladder cancer	0.000209	0.000869	CcSEcCtD
Furosemide—Hyperglycaemia—Epirubicin—urinary bladder cancer	0.000208	0.000865	CcSEcCtD
Furosemide—Somnolence—Etoposide—urinary bladder cancer	0.000208	0.000864	CcSEcCtD
Furosemide—Hepatobiliary disease—Methotrexate—urinary bladder cancer	0.000208	0.000864	CcSEcCtD
Furosemide—Vomiting—Thiotepa—urinary bladder cancer	0.000207	0.000861	CcSEcCtD
Furosemide—Drowsiness—Epirubicin—urinary bladder cancer	0.000206	0.000855	CcSEcCtD
Furosemide—Rash—Thiotepa—urinary bladder cancer	0.000205	0.000853	CcSEcCtD
Furosemide—Dermatitis—Thiotepa—urinary bladder cancer	0.000205	0.000853	CcSEcCtD
Furosemide—Agranulocytosis—Methotrexate—urinary bladder cancer	0.000205	0.000852	CcSEcCtD
Furosemide—Headache—Thiotepa—urinary bladder cancer	0.000204	0.000848	CcSEcCtD
Furosemide—Stevens-Johnson syndrome—Epirubicin—urinary bladder cancer	0.000204	0.000847	CcSEcCtD
Furosemide—Decreased appetite—Etoposide—urinary bladder cancer	0.000203	0.000845	CcSEcCtD
Furosemide—Renal failure—Epirubicin—urinary bladder cancer	0.000202	0.00084	CcSEcCtD
Furosemide—Gastrointestinal disorder—Etoposide—urinary bladder cancer	0.000202	0.000839	CcSEcCtD
Furosemide—Body temperature increased—Cisplatin—urinary bladder cancer	0.000202	0.000839	CcSEcCtD
Furosemide—Fatigue—Etoposide—urinary bladder cancer	0.000202	0.000838	CcSEcCtD
Furosemide—Pain—Etoposide—urinary bladder cancer	0.0002	0.000831	CcSEcCtD
Furosemide—Constipation—Etoposide—urinary bladder cancer	0.0002	0.000831	CcSEcCtD
Furosemide—Hypersensitivity—Fluorouracil—urinary bladder cancer	0.000198	0.000825	CcSEcCtD
Furosemide—Sweating—Epirubicin—urinary bladder cancer	0.000197	0.000819	CcSEcCtD
Furosemide—Pollakiuria—Doxorubicin—urinary bladder cancer	0.000197	0.000819	CcSEcCtD
Furosemide—Asthenia—Gemcitabine—urinary bladder cancer	0.000197	0.000817	CcSEcCtD
Furosemide—Urinary tract disorder—Methotrexate—urinary bladder cancer	0.000195	0.00081	CcSEcCtD
Furosemide—Photosensitivity reaction—Doxorubicin—urinary bladder cancer	0.000195	0.000809	CcSEcCtD
Furosemide—Hepatobiliary disease—Epirubicin—urinary bladder cancer	0.000194	0.000808	CcSEcCtD
Furosemide—Pruritus—Gemcitabine—urinary bladder cancer	0.000194	0.000806	CcSEcCtD
Furosemide—Nausea—Thiotepa—urinary bladder cancer	0.000193	0.000804	CcSEcCtD
Furosemide—Urethral disorder—Methotrexate—urinary bladder cancer	0.000193	0.000804	CcSEcCtD
Furosemide—Feeling abnormal—Etoposide—urinary bladder cancer	0.000193	0.000801	CcSEcCtD
Furosemide—Hyperglycaemia—Doxorubicin—urinary bladder cancer	0.000193	0.0008	CcSEcCtD
Furosemide—Agranulocytosis—Epirubicin—urinary bladder cancer	0.000192	0.000798	CcSEcCtD
Furosemide—Gastrointestinal pain—Etoposide—urinary bladder cancer	0.000191	0.000795	CcSEcCtD
Furosemide—Pruritus—Fluorouracil—urinary bladder cancer	0.000191	0.000792	CcSEcCtD
Furosemide—Drowsiness—Doxorubicin—urinary bladder cancer	0.00019	0.000791	CcSEcCtD
Furosemide—Visual impairment—Methotrexate—urinary bladder cancer	0.00019	0.00079	CcSEcCtD
Furosemide—Stevens-Johnson syndrome—Doxorubicin—urinary bladder cancer	0.000189	0.000784	CcSEcCtD
Furosemide—Hypersensitivity—Cisplatin—urinary bladder cancer	0.000188	0.000782	CcSEcCtD
Furosemide—Diarrhoea—Gemcitabine—urinary bladder cancer	0.000187	0.000779	CcSEcCtD
Furosemide—Renal failure—Doxorubicin—urinary bladder cancer	0.000187	0.000777	CcSEcCtD
Furosemide—Erythema multiforme—Methotrexate—urinary bladder cancer	0.000187	0.000775	CcSEcCtD
Furosemide—Urticaria—Etoposide—urinary bladder cancer	0.000186	0.000772	CcSEcCtD
Furosemide—Abdominal pain—Etoposide—urinary bladder cancer	0.000185	0.000769	CcSEcCtD
Furosemide—Body temperature increased—Etoposide—urinary bladder cancer	0.000185	0.000769	CcSEcCtD
Furosemide—Eye disorder—Methotrexate—urinary bladder cancer	0.000184	0.000766	CcSEcCtD
Furosemide—Diarrhoea—Fluorouracil—urinary bladder cancer	0.000184	0.000766	CcSEcCtD
Furosemide—Tinnitus—Methotrexate—urinary bladder cancer	0.000184	0.000764	CcSEcCtD
Furosemide—Asthenia—Cisplatin—urinary bladder cancer	0.000183	0.000761	CcSEcCtD
Furosemide—Sweating—Doxorubicin—urinary bladder cancer	0.000182	0.000758	CcSEcCtD
Furosemide—Urinary tract disorder—Epirubicin—urinary bladder cancer	0.000182	0.000758	CcSEcCtD
Furosemide—Urethral disorder—Epirubicin—urinary bladder cancer	0.000181	0.000752	CcSEcCtD
Furosemide—Hepatobiliary disease—Doxorubicin—urinary bladder cancer	0.00018	0.000748	CcSEcCtD
Furosemide—Angiopathy—Methotrexate—urinary bladder cancer	0.000179	0.000744	CcSEcCtD
Furosemide—Immune system disorder—Methotrexate—urinary bladder cancer	0.000178	0.00074	CcSEcCtD
Furosemide—Dizziness—Fluorouracil—urinary bladder cancer	0.000178	0.00074	CcSEcCtD
Furosemide—Visual impairment—Epirubicin—urinary bladder cancer	0.000178	0.000739	CcSEcCtD
Furosemide—Agranulocytosis—Doxorubicin—urinary bladder cancer	0.000178	0.000738	CcSEcCtD
Furosemide—Diarrhoea—Cisplatin—urinary bladder cancer	0.000175	0.000726	CcSEcCtD
Furosemide—Erythema multiforme—Epirubicin—urinary bladder cancer	0.000175	0.000725	CcSEcCtD
Furosemide—Vomiting—Gemcitabine—urinary bladder cancer	0.000174	0.000724	CcSEcCtD
Furosemide—Rash—Gemcitabine—urinary bladder cancer	0.000173	0.000718	CcSEcCtD
Furosemide—Dermatitis—Gemcitabine—urinary bladder cancer	0.000173	0.000717	CcSEcCtD
Furosemide—Eye disorder—Epirubicin—urinary bladder cancer	0.000173	0.000717	CcSEcCtD
Furosemide—Hypersensitivity—Etoposide—urinary bladder cancer	0.000172	0.000716	CcSEcCtD
Furosemide—Tinnitus—Epirubicin—urinary bladder cancer	0.000172	0.000715	CcSEcCtD
Furosemide—Erythema—Methotrexate—urinary bladder cancer	0.000172	0.000714	CcSEcCtD
Furosemide—Malnutrition—Methotrexate—urinary bladder cancer	0.000172	0.000714	CcSEcCtD
Furosemide—Headache—Gemcitabine—urinary bladder cancer	0.000172	0.000713	CcSEcCtD
Furosemide—Vomiting—Fluorouracil—urinary bladder cancer	0.000171	0.000712	CcSEcCtD
Furosemide—Rash—Fluorouracil—urinary bladder cancer	0.00017	0.000706	CcSEcCtD
Furosemide—Dermatitis—Fluorouracil—urinary bladder cancer	0.00017	0.000705	CcSEcCtD
Furosemide—Headache—Fluorouracil—urinary bladder cancer	0.000169	0.000701	CcSEcCtD
Furosemide—Urinary tract disorder—Doxorubicin—urinary bladder cancer	0.000169	0.000701	CcSEcCtD
Furosemide—Dysgeusia—Methotrexate—urinary bladder cancer	0.000168	0.000699	CcSEcCtD
Furosemide—Asthenia—Etoposide—urinary bladder cancer	0.000168	0.000698	CcSEcCtD
Furosemide—Angiopathy—Epirubicin—urinary bladder cancer	0.000167	0.000696	CcSEcCtD
Furosemide—Urethral disorder—Doxorubicin—urinary bladder cancer	0.000167	0.000696	CcSEcCtD
Furosemide—Immune system disorder—Epirubicin—urinary bladder cancer	0.000167	0.000693	CcSEcCtD
Furosemide—Pruritus—Etoposide—urinary bladder cancer	0.000166	0.000688	CcSEcCtD
Furosemide—Arrhythmia—Epirubicin—urinary bladder cancer	0.000165	0.000685	CcSEcCtD
Furosemide—Visual impairment—Doxorubicin—urinary bladder cancer	0.000165	0.000684	CcSEcCtD
Furosemide—Nausea—Gemcitabine—urinary bladder cancer	0.000163	0.000676	CcSEcCtD
Furosemide—Vomiting—Cisplatin—urinary bladder cancer	0.000162	0.000675	CcSEcCtD
Furosemide—Vision blurred—Methotrexate—urinary bladder cancer	0.000162	0.000673	CcSEcCtD
Furosemide—Erythema multiforme—Doxorubicin—urinary bladder cancer	0.000162	0.000671	CcSEcCtD
Furosemide—Rash—Cisplatin—urinary bladder cancer	0.000161	0.000669	CcSEcCtD
Furosemide—Dermatitis—Cisplatin—urinary bladder cancer	0.000161	0.000669	CcSEcCtD
Furosemide—Erythema—Epirubicin—urinary bladder cancer	0.000161	0.000668	CcSEcCtD
Furosemide—Malnutrition—Epirubicin—urinary bladder cancer	0.000161	0.000668	CcSEcCtD
Furosemide—Diarrhoea—Etoposide—urinary bladder cancer	0.00016	0.000665	CcSEcCtD
Furosemide—Nausea—Fluorouracil—urinary bladder cancer	0.00016	0.000665	CcSEcCtD
Furosemide—Eye disorder—Doxorubicin—urinary bladder cancer	0.00016	0.000663	CcSEcCtD
Furosemide—Tinnitus—Doxorubicin—urinary bladder cancer	0.000159	0.000662	CcSEcCtD
Furosemide—Anaemia—Methotrexate—urinary bladder cancer	0.000159	0.00066	CcSEcCtD
Furosemide—Flatulence—Epirubicin—urinary bladder cancer	0.000158	0.000658	CcSEcCtD
Furosemide—Dysgeusia—Epirubicin—urinary bladder cancer	0.000157	0.000654	CcSEcCtD
Furosemide—Angiopathy—Doxorubicin—urinary bladder cancer	0.000155	0.000644	CcSEcCtD
Furosemide—Dizziness—Etoposide—urinary bladder cancer	0.000155	0.000643	CcSEcCtD
Furosemide—Muscle spasms—Epirubicin—urinary bladder cancer	0.000155	0.000642	CcSEcCtD
Furosemide—Immune system disorder—Doxorubicin—urinary bladder cancer	0.000154	0.000641	CcSEcCtD
Furosemide—Vertigo—Methotrexate—urinary bladder cancer	0.000154	0.000641	CcSEcCtD
Furosemide—Leukopenia—Methotrexate—urinary bladder cancer	0.000154	0.000639	CcSEcCtD
Furosemide—Arrhythmia—Doxorubicin—urinary bladder cancer	0.000153	0.000634	CcSEcCtD
Furosemide—Nausea—Cisplatin—urinary bladder cancer	0.000152	0.00063	CcSEcCtD
Furosemide—Vision blurred—Epirubicin—urinary bladder cancer	0.000151	0.000629	CcSEcCtD
Furosemide—Vomiting—Etoposide—urinary bladder cancer	0.000149	0.000618	CcSEcCtD
Furosemide—Erythema—Doxorubicin—urinary bladder cancer	0.000149	0.000618	CcSEcCtD
Furosemide—Malnutrition—Doxorubicin—urinary bladder cancer	0.000149	0.000618	CcSEcCtD
Furosemide—Anaemia—Epirubicin—urinary bladder cancer	0.000149	0.000617	CcSEcCtD
Furosemide—Agitation—Epirubicin—urinary bladder cancer	0.000148	0.000614	CcSEcCtD
Furosemide—Rash—Etoposide—urinary bladder cancer	0.000148	0.000613	CcSEcCtD
Furosemide—Dermatitis—Etoposide—urinary bladder cancer	0.000147	0.000613	CcSEcCtD
Furosemide—Headache—Etoposide—urinary bladder cancer	0.000147	0.000609	CcSEcCtD
Furosemide—Flatulence—Doxorubicin—urinary bladder cancer	0.000147	0.000609	CcSEcCtD
Furosemide—Dysgeusia—Doxorubicin—urinary bladder cancer	0.000146	0.000605	CcSEcCtD
Furosemide—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—urinary bladder cancer	0.000145	0.000603	CcSEcCtD
Furosemide—Vertigo—Epirubicin—urinary bladder cancer	0.000144	0.0006	CcSEcCtD
Furosemide—Leukopenia—Epirubicin—urinary bladder cancer	0.000144	0.000598	CcSEcCtD
Furosemide—Muscle spasms—Doxorubicin—urinary bladder cancer	0.000143	0.000594	CcSEcCtD
Furosemide—Confusional state—Methotrexate—urinary bladder cancer	0.000141	0.000587	CcSEcCtD
Furosemide—Anaphylactic shock—Methotrexate—urinary bladder cancer	0.00014	0.000582	CcSEcCtD
Furosemide—Vision blurred—Doxorubicin—urinary bladder cancer	0.00014	0.000582	CcSEcCtD
Furosemide—Nausea—Etoposide—urinary bladder cancer	0.000139	0.000578	CcSEcCtD
Furosemide—Nervous system disorder—Methotrexate—urinary bladder cancer	0.000137	0.000571	CcSEcCtD
Furosemide—Anaemia—Doxorubicin—urinary bladder cancer	0.000137	0.000571	CcSEcCtD
Furosemide—Thrombocytopenia—Methotrexate—urinary bladder cancer	0.000137	0.00057	CcSEcCtD
Furosemide—Agitation—Doxorubicin—urinary bladder cancer	0.000137	0.000568	CcSEcCtD
Furosemide—Skin disorder—Methotrexate—urinary bladder cancer	0.000136	0.000566	CcSEcCtD
Furosemide—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—urinary bladder cancer	0.000136	0.000565	CcSEcCtD
Furosemide—Hyperhidrosis—Methotrexate—urinary bladder cancer	0.000135	0.000563	CcSEcCtD
Furosemide—Dry mouth—Epirubicin—urinary bladder cancer	0.000134	0.000556	CcSEcCtD
Furosemide—Vertigo—Doxorubicin—urinary bladder cancer	0.000134	0.000555	CcSEcCtD
Furosemide—Anorexia—Methotrexate—urinary bladder cancer	0.000134	0.000555	CcSEcCtD
Furosemide—Leukopenia—Doxorubicin—urinary bladder cancer	0.000133	0.000553	CcSEcCtD
Furosemide—Confusional state—Epirubicin—urinary bladder cancer	0.000132	0.00055	CcSEcCtD
Furosemide—Anaphylactic shock—Epirubicin—urinary bladder cancer	0.000131	0.000545	CcSEcCtD
Furosemide—Hypotension—Methotrexate—urinary bladder cancer	0.000131	0.000544	CcSEcCtD
Furosemide—Shock—Epirubicin—urinary bladder cancer	0.000129	0.000536	CcSEcCtD
Furosemide—Nervous system disorder—Epirubicin—urinary bladder cancer	0.000129	0.000535	CcSEcCtD
Furosemide—Thrombocytopenia—Epirubicin—urinary bladder cancer	0.000128	0.000534	CcSEcCtD
Furosemide—Skin disorder—Epirubicin—urinary bladder cancer	0.000127	0.000529	CcSEcCtD
Furosemide—Hyperhidrosis—Epirubicin—urinary bladder cancer	0.000127	0.000527	CcSEcCtD
Furosemide—Paraesthesia—Methotrexate—urinary bladder cancer	0.000126	0.000523	CcSEcCtD
Furosemide—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—urinary bladder cancer	0.000126	0.000522	CcSEcCtD
Furosemide—Anorexia—Epirubicin—urinary bladder cancer	0.000125	0.00052	CcSEcCtD
Furosemide—Somnolence—Methotrexate—urinary bladder cancer	0.000125	0.000518	CcSEcCtD
Furosemide—Dry mouth—Doxorubicin—urinary bladder cancer	0.000124	0.000515	CcSEcCtD
Furosemide—Hypotension—Epirubicin—urinary bladder cancer	0.000123	0.000509	CcSEcCtD
Furosemide—Confusional state—Doxorubicin—urinary bladder cancer	0.000122	0.000509	CcSEcCtD
Furosemide—Decreased appetite—Methotrexate—urinary bladder cancer	0.000122	0.000506	CcSEcCtD
Furosemide—Bumetanide—PTGS2—urinary bladder cancer	0.000122	1	CrCbGaD
Furosemide—Anaphylactic shock—Doxorubicin—urinary bladder cancer	0.000121	0.000504	CcSEcCtD
Furosemide—Gastrointestinal disorder—Methotrexate—urinary bladder cancer	0.000121	0.000503	CcSEcCtD
Furosemide—Fatigue—Methotrexate—urinary bladder cancer	0.000121	0.000502	CcSEcCtD
Furosemide—Pain—Methotrexate—urinary bladder cancer	0.00012	0.000498	CcSEcCtD
Furosemide—Shock—Doxorubicin—urinary bladder cancer	0.000119	0.000496	CcSEcCtD
Furosemide—Nervous system disorder—Doxorubicin—urinary bladder cancer	0.000119	0.000495	CcSEcCtD
Furosemide—Thrombocytopenia—Doxorubicin—urinary bladder cancer	0.000119	0.000494	CcSEcCtD
Furosemide—Skin disorder—Doxorubicin—urinary bladder cancer	0.000118	0.00049	CcSEcCtD
Furosemide—Paraesthesia—Epirubicin—urinary bladder cancer	0.000118	0.000489	CcSEcCtD
Furosemide—Hyperhidrosis—Doxorubicin—urinary bladder cancer	0.000117	0.000488	CcSEcCtD
Furosemide—Somnolence—Epirubicin—urinary bladder cancer	0.000117	0.000485	CcSEcCtD
Furosemide—Anorexia—Doxorubicin—urinary bladder cancer	0.000116	0.000481	CcSEcCtD
Furosemide—Feeling abnormal—Methotrexate—urinary bladder cancer	0.000115	0.00048	CcSEcCtD
Furosemide—Gastrointestinal pain—Methotrexate—urinary bladder cancer	0.000115	0.000476	CcSEcCtD
Furosemide—Decreased appetite—Epirubicin—urinary bladder cancer	0.000114	0.000474	CcSEcCtD
Furosemide—Hypotension—Doxorubicin—urinary bladder cancer	0.000113	0.000471	CcSEcCtD
Furosemide—Gastrointestinal disorder—Epirubicin—urinary bladder cancer	0.000113	0.000471	CcSEcCtD
Furosemide—Fatigue—Epirubicin—urinary bladder cancer	0.000113	0.00047	CcSEcCtD
Furosemide—Pain—Epirubicin—urinary bladder cancer	0.000112	0.000466	CcSEcCtD
Furosemide—Constipation—Epirubicin—urinary bladder cancer	0.000112	0.000466	CcSEcCtD
Furosemide—Urticaria—Methotrexate—urinary bladder cancer	0.000111	0.000463	CcSEcCtD
Furosemide—Abdominal pain—Methotrexate—urinary bladder cancer	0.000111	0.00046	CcSEcCtD
Furosemide—Body temperature increased—Methotrexate—urinary bladder cancer	0.000111	0.00046	CcSEcCtD
Furosemide—Paraesthesia—Doxorubicin—urinary bladder cancer	0.000109	0.000453	CcSEcCtD
Furosemide—Feeling abnormal—Epirubicin—urinary bladder cancer	0.000108	0.000449	CcSEcCtD
Furosemide—Somnolence—Doxorubicin—urinary bladder cancer	0.000108	0.000448	CcSEcCtD
Furosemide—Gastrointestinal pain—Epirubicin—urinary bladder cancer	0.000107	0.000446	CcSEcCtD
Furosemide—Decreased appetite—Doxorubicin—urinary bladder cancer	0.000105	0.000438	CcSEcCtD
Furosemide—Gastrointestinal disorder—Doxorubicin—urinary bladder cancer	0.000105	0.000435	CcSEcCtD
Furosemide—Fatigue—Doxorubicin—urinary bladder cancer	0.000105	0.000435	CcSEcCtD
Furosemide—Urticaria—Epirubicin—urinary bladder cancer	0.000104	0.000433	CcSEcCtD
Furosemide—Pain—Doxorubicin—urinary bladder cancer	0.000104	0.000431	CcSEcCtD
Furosemide—Constipation—Doxorubicin—urinary bladder cancer	0.000104	0.000431	CcSEcCtD
Furosemide—Abdominal pain—Epirubicin—urinary bladder cancer	0.000104	0.000431	CcSEcCtD
Furosemide—Body temperature increased—Epirubicin—urinary bladder cancer	0.000104	0.000431	CcSEcCtD
Furosemide—Hypersensitivity—Methotrexate—urinary bladder cancer	0.000103	0.000429	CcSEcCtD
Furosemide—Asthenia—Methotrexate—urinary bladder cancer	0.000101	0.000418	CcSEcCtD
Furosemide—Feeling abnormal—Doxorubicin—urinary bladder cancer	0.0001	0.000416	CcSEcCtD
Furosemide—Gastrointestinal pain—Doxorubicin—urinary bladder cancer	9.92e-05	0.000412	CcSEcCtD
Furosemide—Pruritus—Methotrexate—urinary bladder cancer	9.92e-05	0.000412	CcSEcCtD
Furosemide—Hypersensitivity—Epirubicin—urinary bladder cancer	9.66e-05	0.000402	CcSEcCtD
Furosemide—Urticaria—Doxorubicin—urinary bladder cancer	9.64e-05	0.000401	CcSEcCtD
Furosemide—Abdominal pain—Doxorubicin—urinary bladder cancer	9.59e-05	0.000399	CcSEcCtD
Furosemide—Body temperature increased—Doxorubicin—urinary bladder cancer	9.59e-05	0.000399	CcSEcCtD
Furosemide—Diarrhoea—Methotrexate—urinary bladder cancer	9.59e-05	0.000398	CcSEcCtD
Furosemide—Asthenia—Epirubicin—urinary bladder cancer	9.41e-05	0.000391	CcSEcCtD
Furosemide—Pruritus—Epirubicin—urinary bladder cancer	9.28e-05	0.000386	CcSEcCtD
Furosemide—Dizziness—Methotrexate—urinary bladder cancer	9.27e-05	0.000385	CcSEcCtD
Furosemide—Diarrhoea—Epirubicin—urinary bladder cancer	8.97e-05	0.000373	CcSEcCtD
Furosemide—Hypersensitivity—Doxorubicin—urinary bladder cancer	8.94e-05	0.000372	CcSEcCtD
Furosemide—Vomiting—Methotrexate—urinary bladder cancer	8.91e-05	0.00037	CcSEcCtD
Furosemide—Rash—Methotrexate—urinary bladder cancer	8.84e-05	0.000367	CcSEcCtD
Furosemide—Dermatitis—Methotrexate—urinary bladder cancer	8.83e-05	0.000367	CcSEcCtD
Furosemide—Headache—Methotrexate—urinary bladder cancer	8.78e-05	0.000365	CcSEcCtD
Furosemide—Asthenia—Doxorubicin—urinary bladder cancer	8.71e-05	0.000362	CcSEcCtD
Furosemide—Dizziness—Epirubicin—urinary bladder cancer	8.67e-05	0.00036	CcSEcCtD
Furosemide—Pruritus—Doxorubicin—urinary bladder cancer	8.59e-05	0.000357	CcSEcCtD
Furosemide—Vomiting—Epirubicin—urinary bladder cancer	8.34e-05	0.000347	CcSEcCtD
Furosemide—Nausea—Methotrexate—urinary bladder cancer	8.33e-05	0.000346	CcSEcCtD
Furosemide—Diarrhoea—Doxorubicin—urinary bladder cancer	8.3e-05	0.000345	CcSEcCtD
Furosemide—Rash—Epirubicin—urinary bladder cancer	8.27e-05	0.000344	CcSEcCtD
Furosemide—Dermatitis—Epirubicin—urinary bladder cancer	8.26e-05	0.000343	CcSEcCtD
Furosemide—Headache—Epirubicin—urinary bladder cancer	8.22e-05	0.000341	CcSEcCtD
Furosemide—Dizziness—Doxorubicin—urinary bladder cancer	8.03e-05	0.000333	CcSEcCtD
Furosemide—Nausea—Epirubicin—urinary bladder cancer	7.79e-05	0.000324	CcSEcCtD
Furosemide—Vomiting—Doxorubicin—urinary bladder cancer	7.72e-05	0.000321	CcSEcCtD
Furosemide—Rash—Doxorubicin—urinary bladder cancer	7.65e-05	0.000318	CcSEcCtD
Furosemide—Dermatitis—Doxorubicin—urinary bladder cancer	7.64e-05	0.000318	CcSEcCtD
Furosemide—Headache—Doxorubicin—urinary bladder cancer	7.6e-05	0.000316	CcSEcCtD
Furosemide—Nausea—Doxorubicin—urinary bladder cancer	7.21e-05	0.0003	CcSEcCtD
Furosemide—CA1—Metabolism—NAT2—urinary bladder cancer	6.79e-05	0.0011	CbGpPWpGaD
Furosemide—ALB—Platelet degranulation—IGF1—urinary bladder cancer	6.74e-05	0.00109	CbGpPWpGaD
Furosemide—CA9—Cellular responses to stress—CXCL8—urinary bladder cancer	6.69e-05	0.00108	CbGpPWpGaD
Furosemide—PGD—Metabolism—NQO1—urinary bladder cancer	6.66e-05	0.00108	CbGpPWpGaD
Furosemide—SLC22A8—Transmembrane transport of small molecules—TFRC—urinary bladder cancer	6.66e-05	0.00108	CbGpPWpGaD
Furosemide—CA9—Metabolism—TYMP—urinary bladder cancer	6.6e-05	0.00107	CbGpPWpGaD
Furosemide—CA7—Metabolism—NQO1—urinary bladder cancer	6.44e-05	0.00104	CbGpPWpGaD
Furosemide—CA5B—Metabolism—NQO1—urinary bladder cancer	6.44e-05	0.00104	CbGpPWpGaD
Furosemide—ALB—Response to elevated platelet cytosolic Ca2+—IGF1—urinary bladder cancer	6.42e-05	0.00104	CbGpPWpGaD
Furosemide—CA4—Metabolism—RRM2—urinary bladder cancer	6.38e-05	0.00103	CbGpPWpGaD
Furosemide—ALB—Metabolism of lipids and lipoproteins—CYP4B1—urinary bladder cancer	6.28e-05	0.00101	CbGpPWpGaD
Furosemide—CA2—Metabolism—RRM2—urinary bladder cancer	6.11e-05	0.000987	CbGpPWpGaD
Furosemide—PGD—Disease—NCOR1—urinary bladder cancer	6.09e-05	0.000984	CbGpPWpGaD
Furosemide—ALB—Folate Metabolism—IL2—urinary bladder cancer	6.04e-05	0.000976	CbGpPWpGaD
Furosemide—CA9—Cellular responses to stress—CDKN1A—urinary bladder cancer	6.03e-05	0.000974	CbGpPWpGaD
Furosemide—CA12—Metabolism—NQO1—urinary bladder cancer	5.97e-05	0.000964	CbGpPWpGaD
Furosemide—CA9—Metabolism—NAT2—urinary bladder cancer	5.97e-05	0.000964	CbGpPWpGaD
Furosemide—CA14—Metabolism—GSTP1—urinary bladder cancer	5.91e-05	0.000954	CbGpPWpGaD
Furosemide—CA4—Metabolism—ENO2—urinary bladder cancer	5.91e-05	0.000954	CbGpPWpGaD
Furosemide—CA4—Metabolism—HPGDS—urinary bladder cancer	5.91e-05	0.000954	CbGpPWpGaD
Furosemide—CA1—Metabolism—RRM2—urinary bladder cancer	5.86e-05	0.000947	CbGpPWpGaD
Furosemide—CA6—Metabolism—GSTP1—urinary bladder cancer	5.76e-05	0.00093	CbGpPWpGaD
Furosemide—CA5A—Metabolism—GSTP1—urinary bladder cancer	5.76e-05	0.00093	CbGpPWpGaD
Furosemide—CA9—Cellular responses to stress—EP300—urinary bladder cancer	5.74e-05	0.000927	CbGpPWpGaD
Furosemide—PGD—Disease—ERCC2—urinary bladder cancer	5.73e-05	0.000925	CbGpPWpGaD
Furosemide—CA4—Metabolism—GSTT1—urinary bladder cancer	5.73e-05	0.000925	CbGpPWpGaD
Furosemide—CA2—Metabolism—ENO2—urinary bladder cancer	5.66e-05	0.000914	CbGpPWpGaD
Furosemide—CA2—Metabolism—HPGDS—urinary bladder cancer	5.66e-05	0.000914	CbGpPWpGaD
Furosemide—SLC22A6—Transmembrane transport of small molecules—TFRC—urinary bladder cancer	5.56e-05	0.000897	CbGpPWpGaD
Furosemide—PGD—Metabolism—GSTP1—urinary bladder cancer	5.55e-05	0.000897	CbGpPWpGaD
Furosemide—CA14—Metabolism—TYMS—urinary bladder cancer	5.49e-05	0.000887	CbGpPWpGaD
Furosemide—CA2—Metabolism—GSTT1—urinary bladder cancer	5.49e-05	0.000887	CbGpPWpGaD
Furosemide—CA14—Metabolism—NCOR1—urinary bladder cancer	5.43e-05	0.000877	CbGpPWpGaD
Furosemide—CA1—Metabolism—ENO2—urinary bladder cancer	5.43e-05	0.000877	CbGpPWpGaD
Furosemide—CA14—Metabolism—GSTM1—urinary bladder cancer	5.43e-05	0.000877	CbGpPWpGaD
Furosemide—CA1—Metabolism—HPGDS—urinary bladder cancer	5.43e-05	0.000877	CbGpPWpGaD
Furosemide—ALB—Vitamin B12 Metabolism—TNF—urinary bladder cancer	5.41e-05	0.000874	CbGpPWpGaD
Furosemide—PGD—Disease—MTHFR—urinary bladder cancer	5.39e-05	0.00087	CbGpPWpGaD
Furosemide—ABCC2—Transmembrane transport of small molecules—TFRC—urinary bladder cancer	5.38e-05	0.000869	CbGpPWpGaD
Furosemide—CA7—Metabolism—GSTP1—urinary bladder cancer	5.37e-05	0.000868	CbGpPWpGaD
Furosemide—CA5B—Metabolism—GSTP1—urinary bladder cancer	5.37e-05	0.000868	CbGpPWpGaD
Furosemide—PGD—Disease—TERT—urinary bladder cancer	5.37e-05	0.000867	CbGpPWpGaD
Furosemide—CA6—Metabolism—TYMS—urinary bladder cancer	5.35e-05	0.000864	CbGpPWpGaD
Furosemide—CA5A—Metabolism—TYMS—urinary bladder cancer	5.35e-05	0.000864	CbGpPWpGaD
Furosemide—CA6—Metabolism—NCOR1—urinary bladder cancer	5.29e-05	0.000854	CbGpPWpGaD
Furosemide—CA5A—Metabolism—NCOR1—urinary bladder cancer	5.29e-05	0.000854	CbGpPWpGaD
Furosemide—CA6—Metabolism—GSTM1—urinary bladder cancer	5.29e-05	0.000854	CbGpPWpGaD
Furosemide—CA5A—Metabolism—GSTM1—urinary bladder cancer	5.29e-05	0.000854	CbGpPWpGaD
Furosemide—CA1—Metabolism—GSTT1—urinary bladder cancer	5.27e-05	0.00085	CbGpPWpGaD
Furosemide—ALB—Transmembrane transport of small molecules—AQP3—urinary bladder cancer	5.24e-05	0.000847	CbGpPWpGaD
Furosemide—CA14—Metabolism—GPX1—urinary bladder cancer	5.2e-05	0.00084	CbGpPWpGaD
Furosemide—ALB—Selenium Micronutrient Network—PTGS2—urinary bladder cancer	5.18e-05	0.000837	CbGpPWpGaD
Furosemide—PGD—Metabolism—TYMS—urinary bladder cancer	5.16e-05	0.000834	CbGpPWpGaD
Furosemide—CA9—Metabolism—RRM2—urinary bladder cancer	5.15e-05	0.000832	CbGpPWpGaD
Furosemide—PGD—Metabolism—GSTM1—urinary bladder cancer	5.1e-05	0.000824	CbGpPWpGaD
Furosemide—PGD—Metabolism—NCOR1—urinary bladder cancer	5.1e-05	0.000824	CbGpPWpGaD
Furosemide—CA14—Metabolism—ERCC2—urinary bladder cancer	5.1e-05	0.000824	CbGpPWpGaD
Furosemide—CA6—Metabolism—GPX1—urinary bladder cancer	5.07e-05	0.000818	CbGpPWpGaD
Furosemide—CA5A—Metabolism—GPX1—urinary bladder cancer	5.07e-05	0.000818	CbGpPWpGaD
Furosemide—CA5B—Metabolism—TYMS—urinary bladder cancer	5e-05	0.000807	CbGpPWpGaD
Furosemide—CA7—Metabolism—TYMS—urinary bladder cancer	5e-05	0.000807	CbGpPWpGaD
Furosemide—CA12—Metabolism—GSTP1—urinary bladder cancer	4.98e-05	0.000804	CbGpPWpGaD
Furosemide—CA5A—Metabolism—ERCC2—urinary bladder cancer	4.97e-05	0.000803	CbGpPWpGaD
Furosemide—CA6—Metabolism—ERCC2—urinary bladder cancer	4.97e-05	0.000803	CbGpPWpGaD
Furosemide—CA7—Metabolism—NCOR1—urinary bladder cancer	4.94e-05	0.000798	CbGpPWpGaD
Furosemide—CA5B—Metabolism—GSTM1—urinary bladder cancer	4.94e-05	0.000798	CbGpPWpGaD
Furosemide—CA5B—Metabolism—NCOR1—urinary bladder cancer	4.94e-05	0.000798	CbGpPWpGaD
Furosemide—CA7—Metabolism—GSTM1—urinary bladder cancer	4.94e-05	0.000798	CbGpPWpGaD
Furosemide—PGD—Disease—FGFR3—urinary bladder cancer	4.93e-05	0.000796	CbGpPWpGaD
Furosemide—PGD—Metabolism—GPX1—urinary bladder cancer	4.89e-05	0.000789	CbGpPWpGaD
Furosemide—PGD—Metabolism—ERCC2—urinary bladder cancer	4.8e-05	0.000775	CbGpPWpGaD
Furosemide—CA14—Metabolism—MTHFR—urinary bladder cancer	4.8e-05	0.000775	CbGpPWpGaD
Furosemide—CA9—Metabolism—ENO2—urinary bladder cancer	4.77e-05	0.000771	CbGpPWpGaD
Furosemide—CA9—Metabolism—HPGDS—urinary bladder cancer	4.77e-05	0.000771	CbGpPWpGaD
Furosemide—CA4—Metabolism—NQO1—urinary bladder cancer	4.76e-05	0.000769	CbGpPWpGaD
Furosemide—CA7—Metabolism—GPX1—urinary bladder cancer	4.73e-05	0.000764	CbGpPWpGaD
Furosemide—CA5B—Metabolism—GPX1—urinary bladder cancer	4.73e-05	0.000764	CbGpPWpGaD
Furosemide—CA6—Metabolism—MTHFR—urinary bladder cancer	4.68e-05	0.000755	CbGpPWpGaD
Furosemide—CA5A—Metabolism—MTHFR—urinary bladder cancer	4.68e-05	0.000755	CbGpPWpGaD
Furosemide—CA7—Metabolism—ERCC2—urinary bladder cancer	4.64e-05	0.00075	CbGpPWpGaD
Furosemide—CA5B—Metabolism—ERCC2—urinary bladder cancer	4.64e-05	0.00075	CbGpPWpGaD
Furosemide—CA12—Metabolism—TYMS—urinary bladder cancer	4.63e-05	0.000748	CbGpPWpGaD
Furosemide—CA9—Metabolism—GSTT1—urinary bladder cancer	4.63e-05	0.000748	CbGpPWpGaD
Furosemide—CA12—Metabolism—NCOR1—urinary bladder cancer	4.58e-05	0.000739	CbGpPWpGaD
Furosemide—CA12—Metabolism—GSTM1—urinary bladder cancer	4.58e-05	0.000739	CbGpPWpGaD
Furosemide—CA2—Metabolism—NQO1—urinary bladder cancer	4.56e-05	0.000737	CbGpPWpGaD
Furosemide—PGD—Metabolism—MTHFR—urinary bladder cancer	4.51e-05	0.000729	CbGpPWpGaD
Furosemide—ALB—Folate Metabolism—TNF—urinary bladder cancer	4.4e-05	0.000711	CbGpPWpGaD
Furosemide—CA12—Metabolism—GPX1—urinary bladder cancer	4.38e-05	0.000708	CbGpPWpGaD
Furosemide—CA1—Metabolism—NQO1—urinary bladder cancer	4.38e-05	0.000707	CbGpPWpGaD
Furosemide—CA7—Metabolism—MTHFR—urinary bladder cancer	4.36e-05	0.000705	CbGpPWpGaD
Furosemide—CA5B—Metabolism—MTHFR—urinary bladder cancer	4.36e-05	0.000705	CbGpPWpGaD
Furosemide—CA12—Metabolism—ERCC2—urinary bladder cancer	4.3e-05	0.000695	CbGpPWpGaD
Furosemide—ALB—Transmembrane transport of small molecules—TRPV1—urinary bladder cancer	4.28e-05	0.000691	CbGpPWpGaD
Furosemide—PGD—Disease—CREBBP—urinary bladder cancer	4.2e-05	0.000678	CbGpPWpGaD
Furosemide—CA9—Cellular responses to stress—TP53—urinary bladder cancer	4.11e-05	0.000663	CbGpPWpGaD
Furosemide—SLC22A11—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	4.08e-05	0.00066	CbGpPWpGaD
Furosemide—CA12—Metabolism—MTHFR—urinary bladder cancer	4.04e-05	0.000653	CbGpPWpGaD
Furosemide—CA4—Metabolism—GSTP1—urinary bladder cancer	3.97e-05	0.000641	CbGpPWpGaD
Furosemide—CA14—Metabolism—PPARG—urinary bladder cancer	3.89e-05	0.000628	CbGpPWpGaD
Furosemide—ALB—Folate Metabolism—TP53—urinary bladder cancer	3.88e-05	0.000627	CbGpPWpGaD
Furosemide—CA9—Metabolism—NQO1—urinary bladder cancer	3.85e-05	0.000621	CbGpPWpGaD
Furosemide—CA2—Metabolism—GSTP1—urinary bladder cancer	3.81e-05	0.000615	CbGpPWpGaD
Furosemide—PGD—Disease—RHOA—urinary bladder cancer	3.8e-05	0.000613	CbGpPWpGaD
Furosemide—CA5A—Metabolism—PPARG—urinary bladder cancer	3.79e-05	0.000612	CbGpPWpGaD
Furosemide—CA6—Metabolism—PPARG—urinary bladder cancer	3.79e-05	0.000612	CbGpPWpGaD
Furosemide—CA14—Metabolism—CREBBP—urinary bladder cancer	3.74e-05	0.000604	CbGpPWpGaD
Furosemide—CA4—Metabolism—TYMS—urinary bladder cancer	3.69e-05	0.000596	CbGpPWpGaD
Furosemide—PGD—Metabolism—PPARG—urinary bladder cancer	3.66e-05	0.000591	CbGpPWpGaD
Furosemide—CA1—Metabolism—GSTP1—urinary bladder cancer	3.65e-05	0.000589	CbGpPWpGaD
Furosemide—CA4—Metabolism—NCOR1—urinary bladder cancer	3.65e-05	0.000589	CbGpPWpGaD
Furosemide—CA4—Metabolism—GSTM1—urinary bladder cancer	3.65e-05	0.000589	CbGpPWpGaD
Furosemide—CA6—Metabolism—CREBBP—urinary bladder cancer	3.64e-05	0.000588	CbGpPWpGaD
Furosemide—CA5A—Metabolism—CREBBP—urinary bladder cancer	3.64e-05	0.000588	CbGpPWpGaD
Furosemide—ALB—Metabolism—GSTZ1—urinary bladder cancer	3.58e-05	0.000579	CbGpPWpGaD
Furosemide—CA7—Metabolism—PPARG—urinary bladder cancer	3.54e-05	0.000572	CbGpPWpGaD
Furosemide—CA5B—Metabolism—PPARG—urinary bladder cancer	3.54e-05	0.000572	CbGpPWpGaD
Furosemide—CA2—Metabolism—TYMS—urinary bladder cancer	3.54e-05	0.000572	CbGpPWpGaD
Furosemide—PGD—Metabolism—CREBBP—urinary bladder cancer	3.51e-05	0.000567	CbGpPWpGaD
Furosemide—PGD—Disease—ERBB2—urinary bladder cancer	3.51e-05	0.000567	CbGpPWpGaD
Furosemide—CA2—Metabolism—NCOR1—urinary bladder cancer	3.5e-05	0.000565	CbGpPWpGaD
Furosemide—CA2—Metabolism—GSTM1—urinary bladder cancer	3.5e-05	0.000565	CbGpPWpGaD
Furosemide—ALB—Selenium Micronutrient Network—TNF—urinary bladder cancer	3.5e-05	0.000565	CbGpPWpGaD
Furosemide—CA4—Metabolism—GPX1—urinary bladder cancer	3.49e-05	0.000564	CbGpPWpGaD
Furosemide—SLC22A5—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	3.44e-05	0.000556	CbGpPWpGaD
Furosemide—PGD—Disease—PTGS2—urinary bladder cancer	3.44e-05	0.000555	CbGpPWpGaD
Furosemide—CA4—Metabolism—ERCC2—urinary bladder cancer	3.43e-05	0.000554	CbGpPWpGaD
Furosemide—CA7—Metabolism—CREBBP—urinary bladder cancer	3.4e-05	0.000549	CbGpPWpGaD
Furosemide—CA5B—Metabolism—CREBBP—urinary bladder cancer	3.4e-05	0.000549	CbGpPWpGaD
Furosemide—ALB—Metabolism—GSTO2—urinary bladder cancer	3.4e-05	0.000549	CbGpPWpGaD
Furosemide—ALB—Metabolism—NAT1—urinary bladder cancer	3.4e-05	0.000549	CbGpPWpGaD
Furosemide—CA1—Metabolism—TYMS—urinary bladder cancer	3.39e-05	0.000548	CbGpPWpGaD
Furosemide—CA1—Metabolism—NCOR1—urinary bladder cancer	3.35e-05	0.000542	CbGpPWpGaD
Furosemide—CA1—Metabolism—GSTM1—urinary bladder cancer	3.35e-05	0.000542	CbGpPWpGaD
Furosemide—CA2—Metabolism—GPX1—urinary bladder cancer	3.35e-05	0.000541	CbGpPWpGaD
Furosemide—ALB—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	3.34e-05	0.00054	CbGpPWpGaD
Furosemide—CA2—Metabolism—ERCC2—urinary bladder cancer	3.29e-05	0.000531	CbGpPWpGaD
Furosemide—CA12—Metabolism—PPARG—urinary bladder cancer	3.28e-05	0.00053	CbGpPWpGaD
Furosemide—CA4—Metabolism—MTHFR—urinary bladder cancer	3.22e-05	0.000521	CbGpPWpGaD
Furosemide—CA1—Metabolism—GPX1—urinary bladder cancer	3.21e-05	0.000519	CbGpPWpGaD
Furosemide—CA9—Metabolism—GSTP1—urinary bladder cancer	3.21e-05	0.000518	CbGpPWpGaD
Furosemide—CA1—Metabolism—ERCC2—urinary bladder cancer	3.15e-05	0.000509	CbGpPWpGaD
Furosemide—CA12—Metabolism—CREBBP—urinary bladder cancer	3.15e-05	0.000509	CbGpPWpGaD
Furosemide—SLC22A8—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	3.12e-05	0.000503	CbGpPWpGaD
Furosemide—ALB—Metabolism—UGT2B7—urinary bladder cancer	3.11e-05	0.000502	CbGpPWpGaD
Furosemide—CA2—Metabolism—MTHFR—urinary bladder cancer	3.09e-05	0.000499	CbGpPWpGaD
Furosemide—CA14—Metabolism—PTGS2—urinary bladder cancer	3.06e-05	0.000494	CbGpPWpGaD
Furosemide—PGD—Disease—CDKN1A—urinary bladder cancer	3e-05	0.000485	CbGpPWpGaD
Furosemide—PGD—Disease—PTEN—urinary bladder cancer	3e-05	0.000484	CbGpPWpGaD
Furosemide—ALB—Platelet activation, signaling and aggregation—IGF1—urinary bladder cancer	2.99e-05	0.000483	CbGpPWpGaD
Furosemide—CA9—Metabolism—TYMS—urinary bladder cancer	2.98e-05	0.000482	CbGpPWpGaD
Furosemide—CA5A—Metabolism—PTGS2—urinary bladder cancer	2.98e-05	0.000482	CbGpPWpGaD
Furosemide—CA6—Metabolism—PTGS2—urinary bladder cancer	2.98e-05	0.000482	CbGpPWpGaD
Furosemide—CA1—Metabolism—MTHFR—urinary bladder cancer	2.96e-05	0.000479	CbGpPWpGaD
Furosemide—CA9—Metabolism—NCOR1—urinary bladder cancer	2.95e-05	0.000476	CbGpPWpGaD
Furosemide—CA9—Metabolism—GSTM1—urinary bladder cancer	2.95e-05	0.000476	CbGpPWpGaD
Furosemide—ALB—Transmembrane transport of small molecules—TFRC—urinary bladder cancer	2.89e-05	0.000466	CbGpPWpGaD
Furosemide—PGD—Metabolism—PTGS2—urinary bladder cancer	2.88e-05	0.000465	CbGpPWpGaD
Furosemide—PGD—Disease—EP300—urinary bladder cancer	2.86e-05	0.000462	CbGpPWpGaD
Furosemide—CA9—Metabolism—GPX1—urinary bladder cancer	2.82e-05	0.000456	CbGpPWpGaD
Furosemide—ALB—Metabolism—CYP4B1—urinary bladder cancer	2.8e-05	0.000452	CbGpPWpGaD
Furosemide—CA5B—Metabolism—PTGS2—urinary bladder cancer	2.78e-05	0.00045	CbGpPWpGaD
Furosemide—CA7—Metabolism—PTGS2—urinary bladder cancer	2.78e-05	0.00045	CbGpPWpGaD
Furosemide—PGD—Disease—SRC—urinary bladder cancer	2.78e-05	0.000449	CbGpPWpGaD
Furosemide—CA9—Metabolism—ERCC2—urinary bladder cancer	2.77e-05	0.000448	CbGpPWpGaD
Furosemide—ALB—Platelet activation, signaling and aggregation—RHOA—urinary bladder cancer	2.74e-05	0.000443	CbGpPWpGaD
Furosemide—CA14—Metabolism—PTEN—urinary bladder cancer	2.67e-05	0.000431	CbGpPWpGaD
Furosemide—ALB—Hemostasis—IFNA2—urinary bladder cancer	2.67e-05	0.000431	CbGpPWpGaD
Furosemide—ALB—Metabolism—SLC19A1—urinary bladder cancer	2.64e-05	0.000427	CbGpPWpGaD
Furosemide—CA4—Metabolism—PPARG—urinary bladder cancer	2.61e-05	0.000422	CbGpPWpGaD
Furosemide—CA9—Metabolism—MTHFR—urinary bladder cancer	2.61e-05	0.000421	CbGpPWpGaD
Furosemide—CA5A—Metabolism—PTEN—urinary bladder cancer	2.6e-05	0.00042	CbGpPWpGaD
Furosemide—CA6—Metabolism—PTEN—urinary bladder cancer	2.6e-05	0.00042	CbGpPWpGaD
Furosemide—SLC22A6—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	2.6e-05	0.00042	CbGpPWpGaD
Furosemide—CA12—Metabolism—PTGS2—urinary bladder cancer	2.58e-05	0.000417	CbGpPWpGaD
Furosemide—ALB—Metabolism—PRSS3—urinary bladder cancer	2.57e-05	0.000416	CbGpPWpGaD
Furosemide—CA14—Metabolism—EP300—urinary bladder cancer	2.55e-05	0.000411	CbGpPWpGaD
Furosemide—ABCC2—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	2.52e-05	0.000407	CbGpPWpGaD
Furosemide—CA4—Metabolism—CREBBP—urinary bladder cancer	2.51e-05	0.000406	CbGpPWpGaD
Furosemide—PGD—Metabolism—PTEN—urinary bladder cancer	2.51e-05	0.000405	CbGpPWpGaD
Furosemide—CA2—Metabolism—PPARG—urinary bladder cancer	2.51e-05	0.000405	CbGpPWpGaD
Furosemide—PGD—Disease—MYC—urinary bladder cancer	2.49e-05	0.000402	CbGpPWpGaD
Furosemide—CA5A—Metabolism—EP300—urinary bladder cancer	2.48e-05	0.000401	CbGpPWpGaD
Furosemide—CA6—Metabolism—EP300—urinary bladder cancer	2.48e-05	0.000401	CbGpPWpGaD
Furosemide—PGD—Disease—EGFR—urinary bladder cancer	2.44e-05	0.000393	CbGpPWpGaD
Furosemide—CA7—Metabolism—PTEN—urinary bladder cancer	2.43e-05	0.000392	CbGpPWpGaD
Furosemide—CA5B—Metabolism—PTEN—urinary bladder cancer	2.43e-05	0.000392	CbGpPWpGaD
Furosemide—CA2—Metabolism—CREBBP—urinary bladder cancer	2.41e-05	0.000389	CbGpPWpGaD
Furosemide—CA1—Metabolism—PPARG—urinary bladder cancer	2.4e-05	0.000388	CbGpPWpGaD
Furosemide—PGD—Metabolism—EP300—urinary bladder cancer	2.39e-05	0.000386	CbGpPWpGaD
Furosemide—CA7—Metabolism—EP300—urinary bladder cancer	2.32e-05	0.000374	CbGpPWpGaD
Furosemide—CA5B—Metabolism—EP300—urinary bladder cancer	2.32e-05	0.000374	CbGpPWpGaD
Furosemide—CA1—Metabolism—CREBBP—urinary bladder cancer	2.31e-05	0.000373	CbGpPWpGaD
Furosemide—PGD—Disease—KRAS—urinary bladder cancer	2.3e-05	0.000372	CbGpPWpGaD
Furosemide—ALB—Platelet activation, signaling and aggregation—IL2—urinary bladder cancer	2.3e-05	0.000371	CbGpPWpGaD
Furosemide—CA12—Metabolism—PTEN—urinary bladder cancer	2.25e-05	0.000363	CbGpPWpGaD
Furosemide—CA12—Metabolism—EP300—urinary bladder cancer	2.15e-05	0.000346	CbGpPWpGaD
Furosemide—CA9—Metabolism—PPARG—urinary bladder cancer	2.11e-05	0.000341	CbGpPWpGaD
Furosemide—ALB—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	2.06e-05	0.000333	CbGpPWpGaD
Furosemide—ALB—Metabolism—TYMP—urinary bladder cancer	2.06e-05	0.000332	CbGpPWpGaD
Furosemide—CA4—Metabolism—PTGS2—urinary bladder cancer	2.06e-05	0.000332	CbGpPWpGaD
Furosemide—CA9—Metabolism—CREBBP—urinary bladder cancer	2.03e-05	0.000328	CbGpPWpGaD
Furosemide—ALB—Platelet activation, signaling and aggregation—SRC—urinary bladder cancer	2.01e-05	0.000324	CbGpPWpGaD
Furosemide—ALB—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	1.98e-05	0.000319	CbGpPWpGaD
Furosemide—CA2—Metabolism—PTGS2—urinary bladder cancer	1.97e-05	0.000319	CbGpPWpGaD
Furosemide—PGD—Disease—HRAS—urinary bladder cancer	1.96e-05	0.000316	CbGpPWpGaD
Furosemide—ALB—Hemostasis—PLAU—urinary bladder cancer	1.89e-05	0.000306	CbGpPWpGaD
Furosemide—CA1—Metabolism—PTGS2—urinary bladder cancer	1.89e-05	0.000305	CbGpPWpGaD
Furosemide—ALB—Metabolism—NAT2—urinary bladder cancer	1.86e-05	0.000301	CbGpPWpGaD
Furosemide—CA4—Metabolism—PTEN—urinary bladder cancer	1.79e-05	0.00029	CbGpPWpGaD
Furosemide—CA2—Metabolism—PTEN—urinary bladder cancer	1.72e-05	0.000278	CbGpPWpGaD
Furosemide—CA4—Metabolism—EP300—urinary bladder cancer	1.71e-05	0.000276	CbGpPWpGaD
Furosemide—CA9—Metabolism—PTGS2—urinary bladder cancer	1.66e-05	0.000268	CbGpPWpGaD
Furosemide—CA1—Metabolism—PTEN—urinary bladder cancer	1.65e-05	0.000266	CbGpPWpGaD
Furosemide—CA2—Metabolism—EP300—urinary bladder cancer	1.64e-05	0.000265	CbGpPWpGaD
Furosemide—ALB—Metabolism—RRM2—urinary bladder cancer	1.61e-05	0.00026	CbGpPWpGaD
Furosemide—CA1—Metabolism—EP300—urinary bladder cancer	1.57e-05	0.000254	CbGpPWpGaD
Furosemide—ALB—Hemostasis—CREBBP—urinary bladder cancer	1.56e-05	0.000252	CbGpPWpGaD
Furosemide—ALB—Hemostasis—IGF1—urinary bladder cancer	1.54e-05	0.000249	CbGpPWpGaD
Furosemide—ALB—Metabolism—HPGDS—urinary bladder cancer	1.49e-05	0.00024	CbGpPWpGaD
Furosemide—ALB—Metabolism—ENO2—urinary bladder cancer	1.49e-05	0.00024	CbGpPWpGaD
Furosemide—ALB—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	1.48e-05	0.000239	CbGpPWpGaD
Furosemide—CA9—Metabolism—PTEN—urinary bladder cancer	1.45e-05	0.000234	CbGpPWpGaD
Furosemide—ALB—Metabolism—GSTT1—urinary bladder cancer	1.44e-05	0.000233	CbGpPWpGaD
Furosemide—ALB—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	1.42e-05	0.00023	CbGpPWpGaD
Furosemide—ALB—Hemostasis—RHOA—urinary bladder cancer	1.41e-05	0.000228	CbGpPWpGaD
Furosemide—CA9—Metabolism—EP300—urinary bladder cancer	1.38e-05	0.000223	CbGpPWpGaD
Furosemide—ALB—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	1.35e-05	0.000218	CbGpPWpGaD
Furosemide—ALB—Metabolism—NQO1—urinary bladder cancer	1.2e-05	0.000194	CbGpPWpGaD
Furosemide—ALB—Hemostasis—IL2—urinary bladder cancer	1.18e-05	0.000191	CbGpPWpGaD
Furosemide—ALB—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	1.16e-05	0.000188	CbGpPWpGaD
Furosemide—ALB—Hemostasis—EP300—urinary bladder cancer	1.06e-05	0.000172	CbGpPWpGaD
Furosemide—ALB—Hemostasis—SRC—urinary bladder cancer	1.03e-05	0.000167	CbGpPWpGaD
Furosemide—ALB—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	1.02e-05	0.000164	CbGpPWpGaD
Furosemide—ALB—Metabolism—GSTP1—urinary bladder cancer	1e-05	0.000162	CbGpPWpGaD
Furosemide—ALB—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	9.68e-06	0.000156	CbGpPWpGaD
Furosemide—ALB—Metabolism—TYMS—urinary bladder cancer	9.3e-06	0.00015	CbGpPWpGaD
Furosemide—ALB—Metabolism—GSTM1—urinary bladder cancer	9.19e-06	0.000148	CbGpPWpGaD
Furosemide—ALB—Metabolism—NCOR1—urinary bladder cancer	9.19e-06	0.000148	CbGpPWpGaD
Furosemide—ALB—Metabolism—GPX1—urinary bladder cancer	8.8e-06	0.000142	CbGpPWpGaD
Furosemide—ALB—Metabolism—ERCC2—urinary bladder cancer	8.64e-06	0.00014	CbGpPWpGaD
Furosemide—ALB—Hemostasis—KRAS—urinary bladder cancer	8.56e-06	0.000138	CbGpPWpGaD
Furosemide—ALB—Metabolism—MTHFR—urinary bladder cancer	8.13e-06	0.000131	CbGpPWpGaD
Furosemide—ALB—Hemostasis—TP53—urinary bladder cancer	7.61e-06	0.000123	CbGpPWpGaD
Furosemide—ALB—Hemostasis—HRAS—urinary bladder cancer	7.28e-06	0.000118	CbGpPWpGaD
Furosemide—ALB—Metabolism—PPARG—urinary bladder cancer	6.59e-06	0.000106	CbGpPWpGaD
Furosemide—ALB—Metabolism—CREBBP—urinary bladder cancer	6.33e-06	0.000102	CbGpPWpGaD
Furosemide—ALB—Metabolism—PTGS2—urinary bladder cancer	5.18e-06	8.37e-05	CbGpPWpGaD
Furosemide—ALB—Metabolism—PTEN—urinary bladder cancer	4.52e-06	7.3e-05	CbGpPWpGaD
Furosemide—ALB—Metabolism—EP300—urinary bladder cancer	4.31e-06	6.96e-05	CbGpPWpGaD
